Empresas derivadas

Aunque no es algo que se espere en absoluto de los investigadores de ICREA, a veces dan con algo que promete convertirse en una potente tecnología nueva pero parece imposible ir más allá en su desarrollo sin una inversión significativa de tiempo y dinero. En estos casos, muchos optan por estudiar la creación de una SPIN OFF.

List of spin off companies

  • MICROOMICS

    Supported by the Institut de Centre de Regulació Genòmica (CRG) and ICREA.
    Entrepreneur: ICREA Research Professor Toni Gabaldón.
    Born in September 2017.


    view details

    CLOSE

    MICROOMICS

    Microomics SL its a Biotech spin-off of the CRG (Centre for Genomic Regulation) specialized in microbiome analysis, being the fist biotech in the national territory that  focuses in metagenomics solutions. We are supported by the CRG (Centre for Genomic Regulation)  and allowed to grow within the exciting environment of the Barcelona Biomedicine Research Park (PRBB). Our business strengths rely on high technical expertise and top-notch research facilities, combined with attractive strategic partnerships and academic collaborations. Our mission is to bring advanced scientific expertise to provide practical solutions to customer and the society as an alternative and innovative approach to new and traditional questions in Biomedicine, Health-Care, Energy, Agrifood, including animal and plan breeding, Consumer Goods Industry and Environmental sectors. We transform metagenomic data into knowledge contributing to society through sustainable growth and improved health and wellbeing.

  • PAPERDROP DIAGNOSTICS

    Supported by the Institut de Nanociència i Nanotecnologia (ICN2) and ICREA.
    Entrepreneur: ICREA Research Professor Arben Merkoçi.
    Born in May 2017.


    view details

    CLOSE

    PAPERDROP DIAGNOSTICS

    PaperDrop Diagnostics S.L. is a nanobiotech company focused on the development of new diagnostic tools.

    Drug-induced injuries (DII) are a little-known public health problem that can cause serious complications and even death. They are caused by kidney or liver failure as a result of adverse drug reactions and/or polypharmacy, the use of four or more medications. This tends to implicate the elderly, which makes DIIs a growing concern in the context of an aging population.

    Currently, early diagnosis of DIIs is non-existent and, when symptoms do present, they can often be misdiagnosed as pertaining to another problem, resulting in a prescription cascade. While this is not so common in the clinical trial setting, where DIIs are a known problem and specialist resources are available for their detection, in its chronic form it is down to primary care physicians to diagnose the DII, who do not typically have access to the necessary resources.

    Paperdrop Diagnostics S.L. proposes a low-cost, easy-to-use device for just such a situation. Its lateral flow immunoassays and microfluidic paper-based analytical devices are being optimised to detect six key biomarkers known to be correlated with the main DIIs: drug-induced kidney injuries, drug-induced liver injuries and systemic inflammatory response syndrome. And it can do so from a single drop of the patient’s blood.

  • QUSIDE

    Supported by the Institut de Ciències Fotòniques (ICFO) and ICREA.
    Entrepeneurs:  ICREA Research Professors Morgan Mitchell and Valerio Pruneri
    Formalised in September 2017.


    view details

    QuSide Technologies S.L. is set up to develop quantum technologies for the cyber-security and super-computation worlds. By exploiting photonics technologies and by leveraging the maturity of the semiconductor manufacturing industry, QuSide products bring unprecedented security and performance to the information era.

  • FUELIUM

    Supported by the Institut de Microelectrònica de Barcelona (IMB-CNM-CSIC) and ICREA.
    Entrepreneur: ICREA Research Professor Neus Sabaté.
    Born in July 2016. 


    view details

    FUELIUM SL develops ecofriendly and single use paper batteries that are able to deliver electrical power to a wide variety of portable devices. The mission of the company is to provide a clean and efficient alternative to conventional button cells.

    FUELIUM batteries are made of paper, carbon and small quantities of non-toxic metals and can be fabricated with low-cost reel-to-reel processes. They are activated by the addition of a single drop of an aqueous liquid: water, urine, plasma/serum, saliva, etc…and can deliver power in the range of miliwatts for several hours. These features make them particularly suitable to power in-vitro diagnostics applications (IVD). The company aims to cover the IVD needs by providing power to digital tests in sectors like woman health monitoring, infectious diseases, drugs of abuse, food analysis or environmental control.

    Compared to their competitors, FUELIUM batteries can be tailored to deliver the energy required by a particular application, they do not generate any harmful or toxic waste – what allows them to be disposed in domestic bins without the need of any recycling procedure - and they reduce manufacturing and integration costs of the devices that require power on-board.

    FUELIUM was founded in 2015 due to the know-how accumulated by the Microfuel cells research group led by Prof. Neus Sabaté at the Institut de Microelectrònica de Barcelona (IMB-CNM-CSIC) and the CSIC patent that protects the technology was licensed to the company in 2016. 

  • KOGENIX THERAPEUTICS

    Jointly supported by Universitat Autònoma de Barcelona (UAB) and ICREA.
    Entrepreneur: ICREA Research professor Miguel Chillón.
    Born in August 2016.


    view details

    CLOSE

    KOGENIX THERAPEUTICS

    Kogenix Therapeutics, Inc. is an early stage gene therapy company developing treatments for debilitating and fatal neurodegenerative diseases. The company plans to develop one-time single dose therapies using adeno-associated virus vectors (AAV) aiming to increase levels of Klotho protein in the brain. The first targeted indications are Alzheimer’s disease (AD) and multiple sclerosis (MS).

    Klotho is a large protein produced in the kidney and brain that acts as a circulating growth factor, involved in neuroprotection, neuroregeneration, remyelination and cognition in the CNS. Thus, Klotho-deficient mice show many signs of human aging including cognitive decline, synaptic loss, abnormal CNS myelin, osteoporosis, atherosclerosis and die prematurely. Moreover, in humans, Klotho levels are very low in the aged brain. In contrast, transgenic Klotho mice live 30% longer, are healthier and smarter, and gene therapy approaches for boosting the level of Klotho protein in the CNS led to significant improvements in memory and cognition.

    The company, based in Boston (US), was founded in August 2016 by Dr. Miguel Chillon, an ICREA researcher at UAB and VHIR, Dr. Assumpció Bosch, Associate Professor, Department of Biochemistry and Molecular Biology at UAB, Dr. Carmela Abraham, Professor of Biochemistry, Pharmacology and Experimental Therapeutics at Boston University (BU), and Menachem Abraham (CEO), Director on the boards of a dozen private and public companies. Kogenix Therapeutics.

Pages